360° SearchNetwork Hot Spots Trends Time Series

Advanced Search Options >>

ViroPharma Inc

Type: Company

Name: ViroPharma Inc

Nationality: United States

Web Address: http://www.viropharma.com/

First reported 18 hours ago - Updated 18 hours ago - 1 reports

ViroPharma Inc

Buyers Accumulate Shares of Viropharma...

One of today's stocks on the move is Viropharma (NASDAQ:VPHM), up 3.5% to $24.57. The S&P is currently trading 0.3% lower to 1,402 and the Dow Jones Industrial Average is trading 0.3% lower to 12,926.ViroPharma Incorporated is a biopharmaceutical company ... [Published Financial News Network online - 18 hours ago]

Entities: ViroPharma Inc, Stocks, Moving Average, Hereditary Angioedema

First reported May 17 2013 - Updated May 17 2013 - 1 reports

Halozyme Reports Pancreatic Cancer Study Data

Halozyme Therapeutics Inc. has released clinical trial data for an experimental cancer drug.Halozyme posted results from an early-stage trial that included its drug PEGPH20 as a treatment for pancreatic cancer. The regimen included PEGPH20 and the cancer ... [Published Drug Discovery and Development - May 17 2013]

Entities: Pancreatic Cancer, Drugs, Tumor, antineoplastic

First reported May 16 2013 - Updated May 16 2013 - 1 reports

Halozyme rises on prostate cancer drug study

NEW YORK -- Shares of Halozyme Therapeutics Inc. climbed Thursday after the company reported clinical trial data for an experimental cancer drug.THE SPARK: Halozyme posted results from an early-stage trial that included its drug PEGPH20 as a treatment ... [Published CNBC - May 16 2013]

Entities: antineoplastic, Prostate Cancer, Drugs, Tumor

First reported May 16 2013 - Updated May 16 2013 - 1 reports

Roche Holding AG

Halozyme Therapeutics Inc (HALO) : Most Active Health Stock

Equitymarketreport.com is devoted to fetch you the most exclusive stocks in the market today. Apart from scanning the markets for the most underrated stocks. We propel those victors directly to your email inbox first ahead of the rest of the marketplace ... [Published SBWire - May 16 2013]

Entities: Halozyme Therapeutics Incorporated, Roche Holding AG, Intrexon Corp, ViroPharma Inc, extracellular

First reported May 16 2013 - Updated May 16 2013 - 1 reports

AVEO Pharmaceuticals Inc

Top New Biotech Ideas from PropThink

The world of biotech investing is always a difficult one. Often a binary event, such as a Food and Drug Administration (FDA) approval or a life-saving capital raise is the difference between not only success or failure, but survival. Combing through reams ... [Published 24/7 Wall St - May 16 2013]

Entities: Biotechnology, AVEO Pharmaceuticals Inc, MAKO Surgical Corp, ViroPharma Inc

First reported May 16 2013 - Updated May 16 2013 - 2 reports

ViroPharma Proudly Supports HAE Day :-) 2013

/PRNewswire/ --HAE Day:-)takes place on 16 May 2013 and aims to raise awareness of Hereditary Angioedema (HAE)ViroPharma Incorporated (NASDAQ: VPHM), today announced its support of the second annual international Hereditary Angioedema Day.HAE Day:-) is ... [Published FinanzNachrichten.de - May 16 2013]

Entities: Hereditary Angioedema, ViroPharma Inc, Patient, Genetic Disorder, Seizures

First reported May 15 2013 - Updated May 15 2013 - 1 reports

ViroPharma reports net loss for Q1, provides outlook for 2013

ViroPharma Incorporated, a biotechnology company, has reported that net loss for the first quarter ended March 31, 2013 was $63.99 million, or $0.98 loss per diluted share, compared to a net income of $19.99 million, or $0.26 per diluted share, for the ... [Published Individual.com - May 15 2013]

Entities: ViroPharma Inc, Cinryze, Virology, Kidney, Biotechnology

First reported May 11 2013 - Updated May 11 2013 - 1 reports

Filings & Reports: ViroPharma

(FinancialWire) (Investrend Information Syndicate) -- Biotechnology company ViroPharma Inc.'s (NASDAQ: VPHM) recently-filed annual and Form 10-K are available for shareholders and potentially interested investors via the Free Annual... ... [Published Individual.com - May 11 2013]

Entities: ViroPharma Inc, Form 10-K, Biotechnology

First reported May 09 2013 - Updated May 09 2013 - 1 reports

ViroPharma To Participate In Two May Healthcare Investor Conferences

SOURCE ViroPharma IncorporatedEXTON, Pa.ViroPharma also announced that Charles Rowland ViroPharma's presentations will be webcast live for investors through www.viropharma.com$ and available for a period of 14 days following the conferences.About ViroPharma ... [Published WMCTV.com - May 09 2013]

Entities: ViroPharma Inc, Health Care, Hereditary Angioedema, Cytomegalovirus

First reported May 03 2013 - Updated May 03 2013 - 1 reports

ViroPharma To Release 2013 First Quarter Financial Results On May 1, 2013

(NewsRx) -- By a News Reporter-Staff News Editor at Biotech Business Week -- ViroPharma Incorporated's (Nasdaq: VPHM) first quarter financial results for 2013 are expected to be released, May 1, 2013 before the open of the U.S. financial markets.The company ... [Published NewsRX - May 03 2013]

Entities: ViroPharma Inc, BusinessWeek, Biotechnology

First reported May 01 2013 - Updated May 01 2013 - 2 reports

ViroPharma's Maribavir: Rising Like Phoenix

Home » Blogs » At Cowen Group's 33rd Annual Health Care Conference held in Boston, MA, early last March, Vincent Milano, President, Chief Executive Officer and Chairman of the Board of Directors of ViroPharma (VPHM), presented an overview of the corporation's ... [Published BioPortfolio - May 01 2013]

Entities: ViroPharma Inc, Phoenix (Arizona, United States), Biotechnology, Milan

First reported May 01 2013 - Updated May 01 2013 - 3 reports

ViroPharma Announces First Quarter 2013 Financial Results

SOURCE ViroPharma Incorporated- Quarterly Global Cinryze® (C1 esterase inhibitor [human]) Net Sales Grew by 46 Percent to $99.5 Million -EXTON, Pa."The early part of 2013 has seen great progress both in our commercial business as well as our development ... [Published CW Richmond WUPV - May 01 2013]

Entities: ViroPharma Inc, Cinryze, Hereditary Angioedema, Cytomegalovirus

Quotes

...of the condition and helps to ensure patients are diagnosed and treated quickly," said Kristina Broadbelt, Director, Global Advocacy, ViroPharma. "At ViroPharma, we have been working with the HAE community for nearly five years. We are delighted to support this year's HAE Day and we are proud of the difference that we may be able to make in patients' lives."

ViroPharma Proudly Supports HAE Day :-) 2013 [Published FinanzNachrichten.de - May 16 2013]

-- Educational Book Abstract: "Pharmacokinetic (PK)/Pharmacodynamic (PD) Results From a Phase 1b Study of PEGylated Hyaluronidase PH20 (PEGPH20) in Combination with Gemcitabine (Gem) in Patients with Pancreatic Cancer" (Abstract # e15005)

Halozyme To Present New Data On PEGPH20 In Pancreatic Cancer At American Society of Clinical Onco ... [Published Zecco - May 15 2013]

...part of 2013 has seen great progress both in our commercial business as well as our development pipeline," stated Vincent Milano, ViroPharma's CEO. "In addition to the virologic response data we will share during our conference call today from subjects enrolled into our two maribavir studies, we also expect results from several key programs for Cinryze in the coming quarters such as subcutaneous Cinryze administration, antibody-mediated rejection (AMR) in kidney transplant, new uses for C1 INH, as well as additional progress updates with maribavir."

ViroPharma reports net loss for Q1, provides outlook for 2013 [Published Individual.com - May 15 2013]

...with the steps we are making towards our near term revenue drivers," said Gregory I Frost, Ph D , President and Chief Executive Officer, Halozyme. "Moreover, over the next 8 weeks, we will present a first-look at clinical data from our innovative pipeline products, PEGPH20 and HTI-501."

Halozyme Reports First Quarter 2013 Financial Results PR Newswire [Published Yahoo! Finance - May 08 2013]

More Content

sort by: Date \| Relevance
Buyers Accumulate Shares of Viropharma... [Published Financial News Network online - 18 hours ago]
PhillyInc: Video-production company Poptent nam... [Published Philadelphia Inquirer - May 22 2013]
Halozyme Reports Pancreatic Cancer Study Data [Published Drug Discovery and Development - May 17 2013]
Halozyme rises on prostate cancer drug study [Published CNBC - May 16 2013]
Halozyme Therapeutics Inc (HALO) : Most Active ... [Published SBWire - May 16 2013]
Top New Biotech Ideas from PropThink [Published 24/7 Wall St - May 16 2013]
ViroPharma Proudly Supports HAE Day :-) 2013 [Published FinanzNachrichten.de - May 16 2013]
ViroPharma Proudly Supports HAE Day :-) 2013 [Published ADVFN UK - May 16 2013]
ViroPharma er stolt over at bakke op om HAE-dag... [Published PR Newswire: Policy & Public Interest - May 16 2013]
ViroPharma unterstützt den HAE Day :-) 2013 und... [Published PR Newswire: Policy & Public Interest - May 16 2013]
Halozyme To Present New Data On PEGPH20 In Panc... [Published Zecco - May 15 2013]
ViroPharma reports net loss for Q1, provides ou... [Published Individual.com - May 15 2013]
Halozyme Therapeutics Management Presents at Ba... [Published Seeking Alpha - May 15 2013]
Shares of Viropharma Receive a Boost, Up 2.3% [Published Individual.com - May 13 2013]
Filings & Reports: ViroPharma [Published Individual.com - May 11 2013]
ViroPharma To Participate In Two May Healthcare... [Published WMCTV.com - May 09 2013]
ViroPharma To Participate In Two May Healthcare... [Published PR Newswire: Health - May 09 2013]
Halozyme Therapeutics Management Discusses Q1 2... [Published Seeking Alpha - May 09 2013]
Halozyme Reports First Quarter 2013 Financial R... [Published Yahoo! Finance - May 08 2013]
Arena Pharmaceuticals, Inc. (ARNA): The Mind-Bl... [Published InsiderMonkey.com - May 07 2013]
TSLA, LORL, ETE, DK, HALO, AFFY Expected To Be ... [Published Individual.com - May 07 2013]
Biota Pharmaceuticals Announces Changes to Its ... [Published Morningstar.com - May 06 2013]
Despite Poor Quarter, ViroPharma's Commercial A... [Published Zecco - May 04 2013]
Despite Poor Quarter, ViroPharma's Commercial A... [Published Seeking Alpha - May 04 2013]
Shares of Impax Laboratories... [Published Financial News Network online - May 03 2013]
ViroPharma To Release 2013 First Quarter Financ... [Published NewsRX - May 03 2013]
ViroPharma Incorporated Given New $38.00 Price ... [Published American Banking News - May 02 2013]
ViroPharma reports encouraging results from Pha... [Published Individual.com - May 02 2013]
The Zacks Analyst Blog Highlights: AT&T, Optime... [Published FinanzNachrichten.de - May 02 2013]
The Zacks Analyst Blog Highlights: AT&T, Optime... [Published Financial Services - May 02 2013]

Blogs

sort by: Date \| Relevance
ViroPharma Earnings: Here’s Why the Stock is Do... [Published Wall St. Cheat Sheet - May 01 2013] ViroPharma Inc. ( NASDAQ:VPHM ) delivered a profit and beat Wall Street’s expectations, BUT came up short on beating the revenue expectation. The revenue miss is a negative sign to shareholders seeking high growth out of the company. Shares are down ...
Cramer: Buy Travelers, ViroPharma, Statoil, and... [Published Wall St. Cheat Sheet - Apr 18 2013] . What do you think about his picks?The Travelers Companies, Inc. ( NYSE:TRV ): Jim Cramer ranked this stock a Buy . Cramer previously ranked this stock a Buy on February 25, 2013. The stock’s 52-week high is $86.61, and its 52-week low is $59.40. “I ...
Cramer: Buy Travelers, ViroPharma, Statoil, and... [Published Wall St. Cheat Sheet - Apr 18 2013] Jim Cramer made the following calls on April 17, 2013. What do you think about his picks? The Travelers Companies, Inc. ( NYSE:TRV ): Jim Cramer ranked this stock a Buy . Cramer previously ranked this stock a Buy on February 25, 2013. The stock’s ...
Jim Cramer: Buy Texas Instruments and These 3 S... [Published Wall St. Cheat Sheet - Mar 11 2013] Jim Cramer made the following calls on March 8th, 2013. What do you think about his picks? Texas Instruments ( NASDAQ:TXN ): Jim Cramer ranked this stock a Buy . Cramer previously ranked this stock a Buy on February 16, 2012. The stock’s 52-week ...
Analysts: Sprint Will Carry NTELOS, and 2 Opini... [Published Wall St. Cheat Sheet - Mar 01 2013] Ansys, Inc. ( NASDAQ:ANSS ): Current Price: $76.16 Baird decided to increase its price target on the company after its Q2 results due to the Ansys’s international strength, rebound in billings, and a rise in licensing revenues. The firm gives ...

Press Releases

sort by: Date \| Relevance
ViroPharma er stolt over at bakke op om HAE-dag... [Published PR Newswire: Policy & Public Interest - May 16 2013]
ViroPharma unterstützt den HAE Day :-) 2013 und... [Published PR Newswire: Policy & Public Interest - May 16 2013]
ViroPharma To Participate In Two May Healthcare... [Published PR Newswire: Health - May 09 2013]
The Zacks Analyst Blog Highlights: AT&T, Optime... [Published Financial Services - May 02 2013]
ViroPharma Announces First Quarter 2013 Financi... [Published PR Newswire: Financial Services - May 01 2013]